stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) EPS (diluted)
NeoGenomics, Inc.'s EPS (diluted) for fiscal 2025 was −$0.84, compared with −$0.62 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.25. Over the past ten years it has ranged from −$1.16 (fiscal 2022) to $0.08 (fiscal 2019); the current reading is higher than 18% of that period. NeoGenomics, Inc. ranks 23rd of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.84 | — |
| FY2024 | −$0.62 | — |
| FY2023 | −$0.70 | — |
| FY2022 | −$1.16 | — |
| FY2021 | −$0.07 | — |
| FY2020 | $0.04 | (50.00%) |
| FY2019 | $0.08 | 177.78% |
| FY2018 | $0.03 | — |
| FY2017 | −$0.14 | — |
| FY2016 | −$0.39 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.06 | — |
| Jun 2026 | $0.02 | — |
| Mar 2026 | −$0.13 | — |
| Dec 2025 | −$0.08 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| CDNA CareDx, Inc. compare | $2.39 |
| VCYT Veracyte, Inc. compare | $1.55 |
| OPK OPKO Health, Inc. compare | −$0.19 |
| NEO NeoGenomics, Inc. | −$0.25 |
| FRNM Freenome, Inc compare | −$0.31 |
| ADPT Adaptive Biotechnologies Corporation compare | −$0.45 |
| CSTL Castle Biosciences, Inc. compare | −$0.77 |
| PSNL Personalis, Inc. compare | −$1.17 |
| WGS GeneDx Holdings Corp. compare | −$3.64 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NEO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement